SynDermix is a Swiss developer of innovative health technologies that focuses on the development of effective and safe treatments that meaningfully respect patient convenience and address important unmet medical needs.
SDX-31 is an electronic medical device platform based on Precisely Modulated Acoustic Energy™ (PMAE) therapy; a proprietary type of treatment during which digitally controlled acoustic frequencies are generated
SDX-21 is a platform based on an endogenous Nitric Oxide (NO) donor in an easy-to-use formulation, which can be leveraged for the development of drug products or medical devices, depending on the selected indication
Together, our executive team, specialist partners and company values combine to sustain ground-breaking health science and process excellence.
Our newsroom provides information on our latest developments and the events we will be attending.
SynDermix is a privately funded company. Investors and other account holders, please click here to log in.